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Genome-Wide Association Studies
Cannot Be Used to Query the
Common Haptoglobin Copy
Number Variant
We recently reported in the Journal that the common biallelic
haptoglobin (Hp) copy number variant (CNV) (rs72294371) is
predictive of coronary heart disease (CHD) among patients with
elevated glycoslylated hemoglobin (HbA1c) (1). In 2 independent
populations, we observed that participants with both the Hp2-2 ge-
notype (homozygous for presence of CNV) and an HbA1c 6.5%
had a 10-fold higher risk of CHD compared with those with at least
1Hp1 allele andHbA1c<6.5% (1). Our study used a candidate gene
approach, and an accompanying editorial (2) suggested that the
recently completed genome wide association (GWA) studies of
millions of single nucleotide polymorphisms (SNPs) should identify
the same genetic predictor of CHD, to conﬁrm our ﬁndings.
However, the HpCNV is not a SNP; it is a 1.7 kb replication, and as
detailed in the following text, our investigations and the work of 2
different groups (3,4) show that currently available GWA studies
cannot tag Hp CNV or identify the association between this variant
and risk of disease.
From our original published investigation of the Hp CNV and
risk of CHD in the Nurses’ Health Study, we also had GWA data
available on 726 women (w700,000 SNPs genotyped using the
Affymetrix Genome-Wide Human 6.0 array, as previously reported
[2]). In this sample, several SNPs were signiﬁcantly associated with
the Hp CNV when we conducted a GWA analysis of the Hp CNV
as either an ordinal endpoint or coded dichotomously; the smallest
p value was w1060, and 48 SNPs were identiﬁed with p values
of <1010. We assessed the 3  3 genotype frequency tables for the
Hp CNV and the SNPs with signiﬁcant p values. Although none
of the SNPs had alleles in perfect correspondence with the Hp
CNV alleles, the contingency tables identiﬁed a few SNPs with
similarities in genotype frequencies as theHpCNV. For example, all
Hp2-2s had the 0 genotype for rs17669033. However, not all
participants with the 0 genotype for rs17669033 had the Hp2-2
genotype, and the overall correlation of rs17669033 and Hp CNV
was r2 ¼ 0.01. Therefore, rs17669033 cannot be used as a surrogate
for the Hp CNV’s genotype.
We used PLINK (5) and Haploview (6) software to calculate
pairwise r2, linkage disequilibrium (LD), and haplotypes between
the Hp CNV and all SNPs 20 kb upstream and downstream of the
Hp CNV on chromosome 16. We used both the genotyped GWA
SNPs, and in addition, included all SNPs from the genome wide
imputations to HapMap (7) phase II (MACH software version
1.0.16) and 1,000G. Many SNPs and 1 haplotype were signiﬁcantly
associated with the Hp polymorphism, but the r2 values observedwere all <0.10, and they could not predict the Hp CNV genotype.
We ran stepwise regression models in SAS (version 9.2; SAS
Institute, Cary, North Carolina) to investigate whether groups of
SNPs could be used to predict the Hp CNV genotype. However,
the highest model r2 we could achieve was r2 ¼ 0.27, when SNPs
from 6 different haplotypes were in the model, and this model did
not predict the Hp CNV genotype. Furthermore, none of the
GWA study groups of SNPs, individual SNPs, or haplotypes
replicated our ﬁndings for the association between the Hp CNV and
risk of CHD. Our data clearly show that currently available GWA
studies have a blind spot for the Hp CNV polymorphism.
Rodriguez et al. (3) used several methods to test for the existence
of tagging SNP(s) for the Hp CNV. Similar to our results, indi-
vidual SNPs and haplotypes were in LD with the Hp CNV with
D0 ¼ 1, but none had r2 values >0.16, and they could not tag the
Hp CNV (3). A similar GWA analysis was also performed in
the Diabetes Heart Study; when LD was assessed using both
D0 and r2 between SNPs and the Hp CNV, no SNPs could tag the
Hp CNV (4). These studies published these results as secondary
ﬁndings, which were not included in abstracts and titles that could
surface in literature reviews, preventing the misconception that the
association between the Hp CNV and CHD could be captured
by GWA (8). It is important to understand the limitations of
GWA studies with polymorphisms such as deletions and CNVs,
and that a direct candidate-gene approach may be necessary for
certain non-SNP polymorphisms. Difﬁculty in tagging non-SNP
polymorphisms with GWA studies has been widely encountered in
complex genomic regions.
In conclusion, we decisively demonstrate in a large population
study of CHD that the Hp CNV polymorphism cannot be iden-
tiﬁed through the use of SNPs. Individual SNPs and haplotypes
can be strongly associated with the Hp CNV without being of any
use as a diagnostic predictor of the Hp CNV genotype. Therefore,
one cannot use GWA studies to query the role of the Hp genotype
in determining the risk of disease. To test whether the interaction
we reported between the Hp CNV genotype and HbA1c on risk of
CHD (1) is replicable in other populations, a study design in which
the Hp CNV is directly assessed in its association with incident
disease is necessary.*Leah E. Cahill, PhD
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Computed Tomography for
Diagnosis of Prosthetic
Valve Endocarditis
Saby et al. (1) should be commended for their recent attempt
to address limitations of modiﬁed Duke Criteria to diagnose
infective endocarditis in patients with prosthetic valve (PVE).
These investigators suggested that abnormal ﬂuorodeoxyglucose
(FDG) uptake on 18F-FDG positron emission tomographic/
computed tomographic (PET/CT) scanning should be included
as a novel major criterion for PVE due to its high sensitivity and
speciﬁcity (1).
However, it should be noted that the false-positive rate may be
underestimated in this study because testing was performed in
patients with high pre-test probability. Abnormal FDG uptake is
not speciﬁc for infectious processes and can be found in various
other common conditions, such as soft atherosclerotic plaques,
vasculitis, thrombi, or malignancy (2,3). Also, cardiac FDG uptake
rates are lower in patients with heart failure and in patients who are
taking drugs such as metformin, ﬁbrate, and synthyroid (4,5).
Further, PVE due to organisms that can form bioﬁlms (e.g.,
Escherichia coli and Candida albicans) might result in high rate of
false-negative tests.
A 18F-FDGPET scan is based on increased uptake of 18F-FDG
by inﬂammatory cells, and it may miss the initial process of leukocyte
migration due to the short half-life of 18F FDG (w110 min).
Diagnostic accuracy of an 18F-FDG PET/CT scan early in thecourse of disease was still not clear in current study (1) because the
scan was performed a median of 9 days after initiation of treatment.
Lower diagnostic accuracy of the modiﬁed Duke Criteria warrant
inclusion of a better diagnostic study that has high sensitivity and
speciﬁcity to localize infectious processes. However, whether revised
criteria to diagnose PVE should include 18F-FDG PET/CT
scanning, single-photon emission computed tomography/CT with
radiolabeled leukocytes scintigraphy (which is reported to have high
diagnostic accuracy to diagnose PVE even in early post-operative
cases), or both, is still not clear and needs to be addressed in
future studies.*Abhishek Sharma, MD
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Imaging 2008;35:95–9.ReplyPositron Emission Tomography/
Computed Tomography for Diagnosis
of Prosthetic Valve Endocarditis
We thank Dr. Sharma for his comments with regard to our recently
published report (1). As demonstrated by this study and then pointed
out by the author of the present letter, Positron emission tomog-
raphy/computed tomography (PET/CT) does not have 100%
speciﬁcity for the diagnosis of prosthetic valve endocarditis (PVE).
Obviously, the diagnostic value of this technique depends on the pre-
test probability, and thus depends on the medical history of the
patients, as well as their clinical, microbiological, and imaging data.
Therefore, the take-home message of our work is not to consider
PET/CT as a technique able to diagnose PVE without other data. It
should be used with the global assessment of the patients with sus-
pected PVE. That is why we recommend considering the results of
this technique in the new 2013 modiﬁed Duke classiﬁcation.
